These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 18161388)
1. Letrozole as adjuvant therapy for postmenopausal women with early breast cancer. Russell CA Manag Care Interface; 2007 Sep; 20(9):30-1, 36. PubMed ID: 18161388 [No Abstract] [Full Text] [Related]
2. Understanding the BIG results: Insights from the BIG 1-98 trial analyses. Wardley AM Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768 [TBL] [Abstract][Full Text] [Related]
3. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole. McArthur HL; Gelmon KA; Olivotto IA; Speers CH; Ellard SL; O'Reilly SE; Kennecke HF J Clin Oncol; 2009 Mar; 27(9):1388-93. PubMed ID: 19237634 [TBL] [Abstract][Full Text] [Related]
5. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. Goss PE; Ingle JN; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Tu D J Clin Oncol; 2008 Apr; 26(12):1948-55. PubMed ID: 18332475 [TBL] [Abstract][Full Text] [Related]
6. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474 [TBL] [Abstract][Full Text] [Related]
7. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen. Carpenter R Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017 [TBL] [Abstract][Full Text] [Related]
8. New breast cancer drug. Brink S US News World Rep; 2001 Dec; 131(26):52. PubMed ID: 11793594 [No Abstract] [Full Text] [Related]
10. Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report. Stilwill SE; Cooper BC J Reprod Med; 2007 Oct; 52(10):979-80. PubMed ID: 17977182 [TBL] [Abstract][Full Text] [Related]
11. Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer. Keating GM Drugs; 2009 Aug; 69(12):1681-705. PubMed ID: 19678717 [TBL] [Abstract][Full Text] [Related]
12. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517 [TBL] [Abstract][Full Text] [Related]
13. Huge response to letrozole in inoperable T4 breast cancer: a case report. Di Cosimo S; Altomare V; Ferretti G; Gravante G; Rabitti C; Rea F; Arullani A; D'Aprile M Clin Ter; 2001; 152(4):263-5. PubMed ID: 11725620 [TBL] [Abstract][Full Text] [Related]
14. Extending the benefits of adjuvant therapy in early HR+ breast cancer. Goss PE Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():45-52. PubMed ID: 18785006 [TBL] [Abstract][Full Text] [Related]
15. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231 [TBL] [Abstract][Full Text] [Related]
16. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449 [TBL] [Abstract][Full Text] [Related]
17. Femara approved as first-line breast cancer therapy. FDA Consum; 2001; 35(3):5. PubMed ID: 11458552 [No Abstract] [Full Text] [Related]
18. Letrozole in postmenopausal hormone-responsive early-stage breast cancer : a viewpoint by Laura B. Michaud. Michaud LB Drugs; 2006; 66(3):363-4. PubMed ID: 16526827 [No Abstract] [Full Text] [Related]
19. Effectiveness of letrozole in the breast cancer treatment continuum. Monnier A Breast; 2006 Feb; 15 Suppl 1():S1-2. PubMed ID: 16500234 [No Abstract] [Full Text] [Related]
20. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. Azim AA; Costantini-Ferrando M; Oktay K J Clin Oncol; 2008 Jun; 26(16):2630-5. PubMed ID: 18509175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]